Chonnam National University Hospital

South Korea Launches First Decentralized Clinical Trial Program with $3.3M Investment

4 months ago

Korea National Enterprise for Clinical Trials (KoNECT) has initiated the country's first decentralized clinical trial (DCT) pilot project, backed by a 4.5 billion won ($3.3 million) government investment over five years. The program, involving seven major medical institutions, will initially focus on approved drugs for mild conditions, allowing patients to participate in trials from home while maintaining regulatory compliance.

Nelonemdaz Shows Promise in Treating Out-of-Hospital Cardiac Arrest Patients

4 months ago

A recent clinical trial has highlighted the potential of Nelonemdaz in treating patients who have suffered out-of-hospital cardiac arrest. The study, supported by the Ministry of Health and Welfare of the Republic of Korea and GNT Pharma, involved multiple institutions and adhered to strict ethical guidelines, offering new hope for improving survival and recovery outcomes.

JLK Receives FDA Clearance for AI-Powered Stroke Diagnosis Solution JLK-PWI

7 months ago

• JLK has secured FDA 510(k) clearance for JLK-PWI, an AI-based solution for analyzing brain MR perfusion images to detect brain infarction areas, marking their fourth FDA approval this year. • A study by Chonnam National University Hospital showed JLK-PWI had a significantly lower lesion detection failure rate (1.9%) in stroke patients compared to Rapid AI (61.4%). • JLK plans to leverage this FDA approval to expand its presence in the U.S. AI healthcare market, which constitutes 59% of the global market, and aims to become a comprehensive stroke solution provider. • With recent funding of 49 billion won, JLK intends to pursue FDA approval for three additional stroke solutions, further solidifying its portfolio of AI-driven medical technologies.

Amlodipine and Candesartan Combination Therapy Shows Superior Efficacy in Treating Hypertension

8 months ago

• A Phase III clinical trial demonstrates that a combination of amlodipine and candesartan is more effective than amlodipine alone in reducing diastolic blood pressure in hypertensive patients. • The study, involving Korean patients with essential hypertension, showed significant reductions in both diastolic and systolic blood pressure with the combination therapy. • The fixed-dose combination of amlodipine and candesartan was well-tolerated, with adverse events comparable to those observed with amlodipine monotherapy. • These findings support the use of amlodipine and candesartan combination therapy as an effective treatment option for patients whose hypertension is not adequately controlled by amlodipine alone.